Low/Intermediate PCA Video Chat, March 10, 2025

by | Mar 12, 2025 | Cancer Resources, Low/Intermediate Prostate Cancer, Prostate Cancer, Recorded Groups

Low/Intermediate PCa

Low/Intermediate PCa Video Chat, March 10, 2025

Low/Intermediate PCa Video Chat, March 10, 2025

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.

WELCOME all to our newly recorded Low/Intermediate Prostate Cancer Group. To receive notice when new recordings are posted, either follow us on this YouTube Channel or sign up to our Blog via https://ancan.org/contact-us/ – check New Blog box.

Join our other free and drop in groups:
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime!

Editor’s Pick: Does BRCA1/2 mutations put a prostate cancer patient at a greater risk for radiation toxicity or secondary cancers? (bj)

Topics Discussed
BRCA1 and toxicity implications when choosing a radiation treatment option; PROMISE Registry; PROSTOX; DECIPHER is not a predictive test — it is a diagnostic test; NCCN and NCI certification; post prostatectomy update and the importance of PSA monitoring; diet and exercise is for controlling and managing PCa; encouraging update 2 years after radiation brachytherapy treatment

Chat Log

David
“The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists,” Carmen Bergom et al., International Journal of Radiation Oncology, v. 105, No. 4, 2019. https://www.redjournal.org/article/S0360-3016(19)33530-8/fulltext

AnCan  – rick
https://bmjoncology.bmj.com/content/4/1/e000592